Sec Form 13D Filing - CPMG Inc filing for PROCEPT BioRobotics Corp (PRCT) - 2022-09-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

(Name of Issuer)

 

(Title of Class of Securities)

 

(CUSIP Number)

 

John Bateman

CPMG, Inc.

2000 McKinney Ave, Suite 2125

Dallas, Texas 75201

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

---

1	NAMES OF REPORTING PERSONS
	CPMG, INC.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☒
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	AF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Texas
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			9,055,341
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			9,055,341
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	9,055,341
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	20.3%
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	CO

1	NAMES OF REPORTING PERSONS
	R. KENT MCGAUGHY, JR.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☒
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	AF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States of America
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			9,169,383
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			9,169,383
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	9,169,383
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	20.6%
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IN, HC

 

(1) This amount includes 67,577 Shares (as defined herein) that are obtainable upon exercise of options granted to the Reporting Person.

1	NAMES OF REPORTING PERSONS
	WHITE TAILED PTARMIGAN, LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			(a)	☐
				(b)	☒
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS)
	WC
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)				☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION
	Texas
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER
			0
		8	SHARED VOTING POWER
			8,955,675
		9	SOLE DISPOSITIVE POWER
			0
		10	SHARED DISPOSITIVE POWER
			8,955,675
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	8,955,675
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)				☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	20.1%
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	PN			& #xA0;

 

 

Item 1 of the Schedule 13D is hereby amended by adding the following:

 

This Amendment No. 2 to Schedule 13D (“Amendment No. 2”) is being filed by the undersigned, pursuant to §240.13d-2(a), with respect to the Common Stock, $0.00001 par value per share (the “Shares”), of PROCEPT BioRobotics Corporation (the “Issuer” or the “Company”), whose principal executive offices are located at 900 Island Drive, Redwood City, California 94065. This Amendment No. 2 amends and supplements the Schedule 13D filed by the Reporting Persons with the U.S. Securities and Exchange Commission (the “SEC”) on September 27, 2021, and Amendment No. 1 filed with the SEC on September 8, 2022 (collectively, “the Schedule 13D”).  Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 2 shall have the meanings given them in the Schedule 13D.

 

 

Item 5 of the Schedule 13D is hereby amended by adding the following:

 

(a, b) As of the date hereof, CPMG may be deemed to be the beneficial owner of 9,055,341 Shares (approximately 20.3% of the total number of Shares outstanding).  This amount includes: (i) 8,955,675 Shares held for the account of WTP, for which CPMG serves as general partner; (ii) 86,156 Shares held for the account of Mallard Fund, L.P., a Texas limited partnership (“Mallard Fund”), for which CPMG serves as investment manager; and (iii) 13,510 Shares held for the account of Kestrel Fund, L.P., a Texas limited partnership (“Kestrel Fund”), for which CPMG serves as investment manager.

 

As of the date hereof, Mr. McGaughy may be deemed to be the beneficial owner of 9,169,383 Shares (approximately 20.6% of the total number of Shares outstanding).  This amount includes (i) 9,055,341 Shares beneficially owned by CPMG and (ii) 114,042 Shares held by Lagos Trust, of which Mr. McGaughy is trustee and has shared voting and dispositive control with Emily M. McGaughy.

 

As of the date hereof, Mr. Desai may be deemed to be the beneficial owner of 9,246,425 Shares (approximately 20.7% of the total number of Shares outstanding). This amount includes: (i) 9,055,341 Shares beneficially owned by CPMG; (ii) 54,641 Shares held directly by Mr. Desai; (iii) 68,866 Shares held by The 2:22 DNA Trust; and (iv) 67,577 Shares that are obtainable upon exercise of options granted to Mr. Desai.

 

As of the date hereof, WTP may be deemed the beneficial owner of 8,955,675 Shares (approximately 20.1% of the total number of Shares outstanding) held for its account.

 

Each of the Reporting Persons exercise shared voting power and shared dispositive power over the 8,955,675 Shares held for the account of WTP. CPMG, Mr. McGaughy and Mr. Desai exercise shared voting power and shared dispositive power over the 86,156 Shares held for the account of Mallard Fund and the 13,510 Shares held for the account of Kestrel Fund.  Mr. McGaughy and his spouse exercise shared voting power and shared dispositive power over the 114,042 Shares held by Lagos Trust.  Mr. Desai and his spouse exercise shared voting power and shared dispositive power over the 68,866 Shares held by The 2:22 DNA Trust.  Mr. Desai exercises sole voting power and sole dispositive power over the 54,641 Shares he holds directly and the 67,577 Shares that are obtainable upon exercise of options granted to Mr. Desai.

 

The beneficial ownership percentages reported herein were calculated in accordance with Rule 13d-3(d)(1)(i) and are based on (1) 44,592,286 Shares outstanding as of July 31, 2022, as reported in the Issuer's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 5, 2022, and, for Mr. Desai, (2) the 67,577 Shares Mr. Desai has the right to acquire upon exercise of options.

 

(c) On September 9, 2022, WTP made an in-kind distribution of 1,119,816 Shares on a pro-rata basis, for no consideration, of which: (i) Mallard Fund received 49,232 Shares; (ii) Kestrel Fund received 7,720 Shares; (iii) Lagos Trust received 65,167 Shares; and (iv) The 2:22 DNA Trust received 11,057 Shares. Except for transactions reported herein, there have been no transactions in the Shares by the Reporting Persons since the filing of Amendment No. 1.

 

(d) No person(s) other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares beneficially owned by the Reporting Persons.

 

(e) This Item 5(e) is not applicable.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

September 13, 2022

 

Attention: Intentional misstatements or omissions of fact constitute federal violations (see 18 U.S.C. 1001)

 

---